clinical trial · NCT04642950
A Phase II/III Study of Sargramostim
Nobelpharma·phase3·completed·n = 70
COVID-19SargramostimPlacebo
brief summary
This is a randomized, placebo-controlled, double-blind, group comparison, multicenter study to evaluate the efficacy and safety of inhalation administration of sargramostim for 5 days, in principle (up to 10 days) as Add-on treatment to the standard treatment in COVID-19 patients.
started
Dec 17, 2020
primary completion
Oct 25, 2021
completion
Oct 25, 2021
last updated
Jul 19, 2024
official title
A Phase II/III Study of Sargramostim in Patients With Coronavirus Disease-2019 (COVID-19)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol